Ioannis‐Alexios Koumprentziotis

Dermatologic Toxicities Associated with Tebentafusp for Uveal Melanoma: A Review of Clinical Trials and Real-World Evidence

Tebentafusp is a first-in-class bispecific fusion protein that redirects T cells toward gp100-expressing cells and represents the first systemic treatment shown to improve overall survival in patients with HLA-A*02:01-positive metastatic uveal melanoma. As gp100 is also expressed...